Last activity: 17.11.2023
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. QUICK FACTS >250 Team members in Tuebingen and Munich, Germany and Houston, Texas >200 Targets covering major solid tumors - 2 proprietary technology platforms, XPRESIDENT® and XCEPTOR® - 7 proprietary drug discovery programs; 3 of which are in clinical development - Multiple partnered programs Read more about Immatics on our homepage: Find us also on Twitter: Twitter: Legal notice:
Location: Germany, Bavaria, Munich
Employees: 201-500
Total raised: $296.385251M
Founded date: 2000

Investors 5

Funding Rounds 5

04.10.2017Series E$58M-
16.07.2014Series D$45.987396...-
15.10.2013Series D$46.446501...-
21.09.2010Series C$70.951354...-

Mentions in press and media 48

17.11.2023Is This European Biotech Startup Revolutionizing Immunothera...Key Takeaways: Company: immatics biotechnologies Industry: Biotechnology, Medical, Therapeutics Loca...eustartup....
11.09.2023Moderna and Immatics jointly develop innovative oncology the...Moderna, Inc. and Immatics N.V. enter into a multi-billion dollar strategic research and
24.07.2023Immatics Announces $35 Million Equity Investment from Bristo...-globenewsw...
17.11.2022Immatics veröffentlicht Ergebnisse des dritten Quartals 2022...Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt h...einpresswi...
17.11.2022Immatics Announces Third Quarter 2022 Financial Results and ...Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high con...einpresswi...
10.10.2022Immatics Reports Interim Clinical Data Update on ACTengine® ...Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation...globenewsw...
10.10.2022Immatics Announces $110 Million Underwritten Offering of Ord...Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), ...globenewsw...
10.09.2022Immatics Presents Comprehensive Preclinical Data Set for TCR...TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presen...globenewsw...
23.08.2022Immatics Announces First Cancer Patient Treated with Second-...IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-recepto...globenewsw...
09.08.2022Immatics Announces Second Quarter 2022 Financial Results and...ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: I...globenewsw...
Show more